Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
52.23 USD   +2.03%
11/10Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
11/04RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperform Rating
MT
11/03Intra-Cellular Therapies Reports Narrower Q3 Loss, Higher Revenue; Shares Jump
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The CompanyÔÇÖs subsidiaries are ITI, Inc. (ITI) and ITI Limited.

Number of employees : 512 people.
Sales per Business
20202021Delta
Small Molecule Drugs22.81100%83.80100% +267.35%
USD in Million
Sales per region
20202021Delta
United States22.81100%83.80100% +267.35%
USD in Million
Managers
Name Title Age Since
Sharon Mates Chairman, President & Chief Executive Officer 68 2013
Lawrence Hineline Chief Financial Officer, Treasurer & SVP-Finance 64 -
Robert Davis Chief Scientific Officer & Senior Vice President 70 2015
Suresh Durgam Chief Medical Officer & Senior Vice President - -
Karen Sheehy Chief Compliance Officer & Senior Vice President 59 2019
Juan F. Sanchez, Dr. VP-Communications & Investor Relations - 2014
Michael Halstead Secretary, Executive VP & General Counsel 48 -
Mark Neumann Vice President-Marketing - -
Michael Olchaskey Senior Vice President & Head-Regulatory Affairs - 2018
John A. Bardi SVP-Market Access, Policy & Government Affairs - 2019
Members of the board
Name Title Age Since
Sharon Mates Chairman, President & Chief Executive Officer 68 2013
Joel Marcus Independent Director 73 2013
Rory Balfour Riggs Independent Director 67 2014
Robert L. van Nostrand Lead Independent Director 64 -
Michael Rawlins, Dr. Independent Director 79 2021
Rene E. Salas Independent Director 59 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 94,705,054 92,230,238 97.4% 0 0.0% 97.4%
Shareholders
NameEquities%
The Vanguard Group, Inc. 7,849,689 8.32%
Fidelity Management & Research Co. LLC 6,080,963 6.44%
Wasatch Advisors, Inc. 5,391,065 5.71%
Alafi Capital Co. LLC 4,668,770 4.95%
Wellington Management Co. LLP 4,463,358 4.73%
Bellevue Asset Management AG 3,349,379 3.55%
Marshall Wace LLP 2,519,764 2.67%
BlackRock Fund Advisors 2,180,977 2.31%
AllianceBernstein LP 2,112,587 2.24%
SSgA Funds Management, Inc. 1,919,815 2.03%
Company contact information
Intra-Cellular Therapies, Inc.
430 East 29th Street
Suite 900
New York, NY 10016

Phone : +1.464.440.9333
Fax : +1.464.440.9334
Web : http://www.intracellulartherapies.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Intra-Cellular Therapies, Inc.